medrxiv
preprint
abstract
object
coronaviru
diseas
becom
pandem
world
need
iggigm
combin
antibodi
test
boom
data
diagnost
index
evalu
inadequ
aim
studi
evalu
diagnost
index
rapid
iggigm
combin
antibodi
test
method
total
patient
enrol
serum
collect
iggigm
combin
antibodi
test
correspond
nasal
pharyng
swab
specimen
collect
rtpcr
accord
rtpcr
result
patient
studi
categor
pcr
posit
group
patient
pcr
neg
group
patient
result
pcr
posit
sampl
test
posit
iggigm
test
kit
yield
sensit
meanwhil
pcr
neg
sampl
sampl
detect
posit
result
specif
posit
predict
valu
neg
predict
valu
accuraci
test
kit
respect
kappa
effici
iggigm
test
kit
rtpcr
accuraci
mildcommon
severecrit
subgroup
respect
accuraci
clinic
confirm
suspect
case
diseas
subgroup
respect
patient
divid
group
accord
time
ill
onset
sampl
collect
sensit
specif
accuraci
three
group
respect
conclus
sensit
specif
easeofus
iggigm
combin
test
kit
adequ
plu
short
turnaround
time
specif
requir
addit
equip
skill
technician
collect
contribut
compet
mass
test
current
stage
take
place
nucleic
acid
rtpcr
serv
complementari
option
rtpcr
combin
rtpcr
iggigm
combin
test
kit
could
provid
insight
infect
diagnosi
decemb
sever
case
pneumonia
unknown
etiolog
known
coronaviru
diseas
occur
wuhan
china
recogn
pandem
world
health
organ
diseas
rapidli
spread
wuhan
provinc
china
around
world
name
new
viru
caus
earli
detect
earli
report
earli
isol
earli
diagnosi
earli
manag
prove
use
cours
patient
detect
earli
unmet
demand
front
medic
personnel
well
known
global
viru
nucleic
acid
high
throughput
sequenc
viru
nucleic
acid
rtpcr
assay
standard
recommend
method
detect
caus
pandem
across
whole
world
high
throughput
sequenc
act
golden
standard
highli
restrict
resourcedepend
platform
especi
resourcelimit
set
viru
nucleic
acid
rtpcr
assay
also
suffer
limit
long
turnaround
time
requir
certifi
laboratori
skill
technician
expens
equip
especi
fals
neg
result
gener
speak
rtpct
result
affect
mani
factor
qualiti
sampl
degener
viru
rna
improp
sampl
nasal
pharyng
swab
former
studi
reveal
case
continu
pcr
neg
chest
ct
scan
posit
result
final
pcr
confirm
posit
seri
continu
rtpcr
test
inevit
hinder
pandem
control
limit
outbreak
contain
effort
agreement
similar
studi
relat
sar
whose
result
show
rtpcr
posit
rate
addit
number
varieti
diagnost
test
expand
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
base
fact
sever
scope
current
situat
around
globe
necessit
greater
test
capac
current
avail
therefor
detect
method
faster
conveni
complementari
nucleic
acid
detect
particularli
import
current
epidem
prevent
control
henc
detect
antibodi
becam
supplement
option
rtpcr
matter
igm
igg
combin
provid
anoth
key
piec
evid
diagnosi
viral
infect
new
coronaviru
pneumonia
prevent
control
program
edit
publish
nation
health
commiss
china
also
recommend
suspici
case
togeth
posit
igmigg
antibodi
deem
posit
case
howev
data
concentr
sensit
specif
inadequ
paramount
valu
decis
whether
use
igmigg
antibodi
detect
aim
studi
evalu
sensit
specif
accuraci
posit
predict
valu
ppv
neg
predict
valu
npv
especi
kappa
effici
pcr
antiinterfer
abil
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
case
connect
tissu
diseas
case
scleroderma
case
common
injuri
underli
diseas
studi
approv
ethic
commiss
gener
hospit
central
theatr
command
sampl
collect
approxim
ml
fast
blood
sampl
drawn
enrol
particip
collect
serum
separ
hose
subsequ
centrifug
g
min
serum
sampl
use
detect
iggigm
antibodi
correspond
nasal
pharyng
swab
specimen
also
collect
rtpcr
data
analysi
spss
use
statist
analysi
test
bilater
p
less
consid
statist
signific
chisquar
test
fisher
exact
probabl
test
use
compar
count
data
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
kappa
effici
calcul
describ
method
section
c
line
appear
test
otherwis
test
invalid
either
g
line
appear
red
line
show
presenc
igg
igm
antibodi
detect
sampl
repres
pictur
five
patient
blood
test
result
shown
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
result
patient
posit
igm
igg
antibodi
pcr
posit
group
divid
two
subgroup
mildcommon
severecrit
subgroup
pcr
neg
group
divid
three
subgroup
clinic
confirm
suspect
case
diseas
subgroup
tabl
pcr
result
subgroup
constant
diagnost
index
except
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
accord
previou
studi
igm
antibodi
could
detect
patient
blood
day
sar
infect
igg
antibodi
could
determin
day
sar
infect
caus
belong
larg
famili
caus
sar
henc
import
calcul
diagnost
index
test
kit
stratifi
time
ill
onset
infect
time
sampl
collect
total
inpati
includ
pcr
confirm
posit
case
clinic
confirm
case
suspect
case
divid
three
group
accord
time
ill
onset
sampl
collect
day
group
day
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
group
day
group
tabl
test
kit
studi
perform
worst
day
group
gener
sensit
accuraci
test
kit
perform
best
day
group
yield
sensit
togeth
accuraci
though
rel
low
specif
day
group
diagnost
index
test
kit
sensit
specif
accuraci
respect
past
week
start
behav
lot
like
onceinacenturi
pathogen
intern
expert
worri
symptom
covid
uniqu
similar
diseas
test
way
know
sure
someon
infect
mass
test
therefor
paramount
import
curb
epidem
viru
nucleic
acid
rtpcr
suitabl
larg
scale
screen
owe
inher
properti
contrari
qualit
detect
igg
igm
antibodi
human
serum
configur
like
home
pregnanc
test
abil
mass
test
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
rule
thumb
igm
mainli
found
blood
lymph
fluid
first
antibodi
individu
made
new
viru
infect
detect
patient
blood
day
igg
abund
type
antibodi
could
measur
day
posit
igm
igg
test
antibodi
detect
patient
blood
sampl
mean
like
individu
becam
infect
recent
earli
stage
infect
igg
posit
probabl
person
infect
sometim
past
late
stage
viru
infect
henc
order
applic
differ
stage
combin
detect
igg
igm
antibodi
recommend
easeofus
iggigm
combin
test
kit
studi
develop
base
gold
immunochromatographi
assay
gica
gener
result
less
minut
human
serum
without
laboratori
equip
skill
personnel
sampl
transport
diagnost
index
socal
test
characrist
includ
sensit
specif
ppv
npv
accuraci
evalu
determin
diagnost
use
result
reveal
abovement
five
index
respect
agreement
recent
publish
research
studi
sensit
specif
sensit
abil
diagnos
diseas
correctli
identifi
posit
test
definit
sensit
suggest
manufactur
tri
improv
iggigm
test
kit
detect
sensit
lower
sensit
falseneg
case
falseposit
case
confirm
detect
method
henc
falseneg
case
would
pose
opportun
infect
peopl
contact
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
examin
one
week
strongli
suggest
kappa
effici
also
investig
studi
kappa
p
inflect
moder
agreement
iggigm
test
kit
rtpcr
assay
accuraci
iggigm
test
kit
clinic
confirm
case
show
case
test
posit
iggigm
test
kit
rtpcr
result
neg
tabl
infect
start
lung
upper
respiratori
tract
henc
sampl
process
larg
effect
final
rtpcr
result
might
partial
explain
high
falseneg
rate
howev
effect
iggigm
test
kit
venou
blood
need
test
iggigm
test
kit
like
remedi
fals
neg
inher
respiratori
swab
sampl
serv
complementari
option
rtpcr
compar
similar
studi
one
strength
record
detail
time
patient
ill
onset
sampl
collect
result
tabl
see
case
posit
pcr
result
group
test
posit
iggigm
test
kit
gener
sensit
time
ill
onset
sampl
collect
patient
group
day
patient
group
may
initi
stage
window
period
infect
concentr
antibodi
low
detect
subgroup
subgroup
sensit
iggigm
test
kit
jump
wherea
specif
two
group
rel
low
respect
difficult
explain
unsur
low
specif
caus
fals
neg
result
rtpcr
take
high
fals
neg
rate
rtpcr
consider
fals
posit
result
iggigm
test
kit
small
sampl
size
strength
studi
enrol
patient
diagnos
autoimmun
diseas
sjogren
syndrom
system
lupu
erythematosu
rheumatoid
arthriti
connect
tissu
diseas
enrol
patient
determin
iggigm
test
kit
antiinterfer
abil
result
show
iggigm
test
kit
perform
well
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
howev
limit
also
point
first
due
limit
time
diagnost
index
evalu
serum
blood
sampl
type
fingertip
blood
plasma
second
small
sampl
size
also
taken
consider
sensit
specif
easeofus
iggigm
combin
test
kit
good
plu
short
turnaround
time
specif
requir
addit
equip
skill
technician
collect
contribut
compet
mass
test
current
stage
take
place
nucleic
acid
rtpcr
serv
complementari
option
rtpcr
combin
rtpcr
iggigm
combin
test
kit
could
provid
insight
infect
diagnosi
author
declar
compet
financi
interest
